Randy F. Sweis, MD

Articles

Dr Sweis on Next Steps for the Investigation of XmAb819 in RCC and Beyond

October 31st 2025

Randy F. Sweis, MD, explains future avenues for the investigation for XmAb819 in tumor types beyond renal cell carcinoma.

Dr Sweis on the Potential for XmAb819 to Fill Treatment Gaps in Refractory RCC

October 24th 2025

Randy F. Sweis, MD, discusses shares how XmAb819 may address the need for effective therapies after progression on standard regimens in RCC.

Dr Sweis on the Expected Safety Profile of XmAb819 in RCC

October 17th 2025

Randy F. Sweis, MD, discusses potential toxicities and mitigation strategies associated with the bispecific T-cell engager XmAb819.

Dr Sweis on the Mechanism of Action of XmAb819 in RCC

October 10th 2025

Randy F. Sweis, MD, explains the mechanism of action of the ENPP3/CD3–targeted bispecific T-cell engager XmAb819 in renal cell carcinoma.

Dr Sweis on Targeting ENPP3 in Clear Cell Renal Cell Carcinoma

October 2nd 2025

Randy F. Sweis, MD, discusses the potential utility of ENPP3 as a therapeutic target in RCC.

Immune System Agents May Move Into Earlier Settings in GU Cancers

June 13th 2019

Over the past 5 years, medical oncologists have witnessed the revolutionary impact of immunotherapy on patients with advanced urologic malignancies. Over the next 5 years, these therapies likely will similarly transform urologic surgical care.

Dr. Sweis on the Management of TKI-Associated Adverse Events in Kidney Cancer

February 14th 2019

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the management of TKI-associated adverse events in kidney cancer.

Dr. Sweis on Immunotherapy Combinations in Kidney Cancer

October 25th 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses immunotherapy combinations in kidney cancer.

Dr. Sweis on Sequencing of Therapies in Prostate Cancer

October 12th 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the sequencing of therapies in prostate cancer.

Dr. Sweis on the Frequency of Immune-Related Adverse Events in Kidney Cancer

September 28th 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the frequency of immune-related adverse events (irAEs).

Dr. Sweis on Immunotherapy in Genitourinary Cancer

September 22nd 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the use of immunotherapy in genitourinary cancer.

Dr. Sweis on Trend Toward Immunotherapy in GU Malignancies

October 3rd 2016

Randy F. Sweis, MD, clinical instructor, University of Chicago Medicine, discusses the trend toward immunotherapy in the field of genitourinary malignancies.